9 Multiple Myeloma Clinical Trials in Hackensack, NJ (2026)

Q: How do I join a clinical trial in Hackensack?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you.

Recruiting Multiple Myeloma Studies in Hackensack

NCT02343042Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...

Hackensack, NJPHASE1300 participantsKaryopharm Therapeutics Inc

View Study Details

NCT05372354Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Mul...

Hackensack, NJPHASE1260 participantsBristol-Myers Squibb

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Hackensack, NJPHASE1246 participantsBeiGene

View Study Details

NCT06121843Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...

Hackensack, NJPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05651932Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent...

Hackensack, NJPHASE1165 participantsK36 Therapeutics, Inc.

View Study Details

NCT06630806Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 wil...

Hackensack, NJPHASE187 participantsSanofi

View Study Details

NCT06988488Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRM...

Hackensack, NJPHASE162 participantsCelgene

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Hackensack, NJPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT03909412Recruiting

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/...

Hackensack, NJPHASE118 participantsHackensack Meridian Health

View Study Details

About Multiple Myeloma Clinical Trials in Hackensack

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 9 multiple myeloma clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 1,375 participants. Research is being sponsored by Karyopharm Therapeutics Inc, Bristol-Myers Squibb, BeiGene and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Hackensack — FAQ

Are there multiple myeloma clinical trials in Hackensack?

Yes, there are 9 multiple myeloma clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 9 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 20, 2026 from ClinicalTrials.gov